Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and most costly cancer to treat due to greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon advanced optical designs and light sensors.
The CSE Technology sector is a platform for new adaptive technology companies to list within an environment that encourages aggressive innovation, research, and development.